Mild Cognitive Impairment and Alzheimer'
Conditions
Interventions
In addition to standard brain 18F-flutemetamol PET/CT imaging, additional neck-to-knee whole-body PET/CT imaging including low-dose CT will be performed for research purposes. The additional acquisiti
Sponsors
Kyoto Prefectural University of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Adults aged 20 years or older diagnosed with mild cognitive impairment (MCI) or mild Alzheimer's disease Patients scheduled to undergo clinically indicated 18F-flutemetamol PET/CT at our institution Individuals who provide written informed consent for study participation
Exclusion criteria
Exclusion criteria: Individuals with contraindications to PET examination (e.g., severe allergy history) Individuals unable or unwilling to provide informed consent Minors, pregnant women, or women with possible pregnancy Patients with severe cognitive impairment judged incapable of providing informed consent Individuals considered unsuitable for study participation by the investigator or treating physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Presence, distribution, and quantitative uptake (SUV) of 18F-flutemetamol in whole-body organs and their association with cerebral amyloid deposition. | — |
Secondary
| Measure | Time frame |
|---|---|
| Association between APOE genotype, particularly APOE epsilon 4, and whole-body amyloid uptake. Association between blood/cerebrospinal fluid biomarkers (Abeta1-40, Abeta1-42, Abeta42/40 ratio, and phosphorylated tau) and whole-body amyloid uptake. Association between whole-body amyloid uptake patterns and clinical manifestations, including cognitive impairment, heart failure, and arrhythmia. Association between extracranial amyloid uptake, including gastrointestinal involvement, and cerebral amyloid deposition. | — |
Countries
Japan
Contacts
Public ContactTomoya Kotani
Kyoto Prefectural University of Medicine Radiology
Outcome results
None listed